VTGN•prnewswire•
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Summary
LOS ANGELES, Jan. 29, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen" or "the Company") (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 29, 2026 by prnewswire